Anthony H V Schapira

List of Publications by Citations

377 papers	38,204 citations	96 h-index	187 g-index
428 ext. papers	42,540 ext. citations	8.8 avg, IF	7.68 L-index

#	Paper	IF	Citations
377	Non-motor symptoms of Parkinson's disease: diagnosis and management. *Lancet Neurology, The*, **2006**, 5, 235-45	24.1	1757
376	Mitochondrial complex I deficiency in Parkinson's disease. *Journal of Neurochemistry*, **1990**, 54, 823-7	6	1619
375	Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. *Lancet Neurology, The*, **2009**, 8, 464-74	24.1	1123
374	Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. *Lancet Neurology, The*, **2008**, 7, 583-90	24.1	1075
373	Mitochondrial complex I deficiency in Parkinson's disease. *Lancet, The*, **1989**, 1, 1269	40	1044
372	Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. *FEBS Letters*, **1994**, 345, 50-4	3.8	964
371	Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. *Human Molecular Genetics*, **2010**, 19, 4861-70	5.6	680
370	Mitochondria in the aetiology and pathogenesis of Parkinson's disease. *Lancet Neurology, The*, **2008** , 7, 97-109	24.1	663
369	International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. *Movement Disorders*, **2006**, 21, 916-23	7	663
368	The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. *Movement Disorders*, **2007**, 22, 1901-11	7	638
367	Mitochondrial defect in Huntington's disease caudate nucleus. *Annals of Neurology*, **1996**, 39, 385-9	9.4	624
366	Non-motor features of Parkinson disease. *Nature Reviews Neuroscience*, **2017**, 18, 435-450	13.5	621
365	Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. *Journal of Neurochemistry*, **1990**, 55, 2142-5	6	606
364	Missing pieces in the Parkinson's disease puzzle. *Nature Medicine*, **2010**, 16, 653-61	50.5	521
363	Mitochondrial disease. *Lancet, The*, **2006**, 368, 70-82	40	491
362	Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. *Lancet, The* , **1992**, 339, 1375-7	40	414
361	Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. *Annals of Neurology*, **1992**, 32 Suppl, S82-7	9.4	402

360	Biochemical abnormalities and excitotoxicity in Huntington's disease brain. *Annals of Neurology*, **1999**, 45, 25-32	9.4	393
359	Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. *Annals of Neurology*, **2012**, 72, 455-63	9.4	384
358	Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. *Movement Disorders*, **2007**, 22, 1623-9	7	375
357	Chaperone-mediated autophagy markers in Parkinson disease brains. *Archives of Neurology*, **2010**, 67, 1464-72		364
356	A novel □synuclein missense mutation in Parkinson disease. *Neurology*, **2013**, 80, 1062-4	6.5	340
355	Mitochondrial diseases. *Lancet, The*, **2012**, 379, 1825-34	40	336
354	Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. *Journal of Neurochemistry*, **1992**, 58, 786-9	6	335
353	Priorities in Parkinson's disease research. *Nature Reviews Drug Discovery*, **2011**, 10, 377-93	64.1	317
352	Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. *Annals of Neurology*, **1994**, 35, 38-44	9.4	304
351	Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. *Brain*, **1992**, 115 (Pt 2), 333-42	11.2	301
350	Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. *Annals of Neurology*, **1992**, 32, 782-8	9.4	301
349	Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 11492-5	11.5	298
348	Analyses of mitochondrial respiratory chain function and mitochondrial DNA deletion in human skeletal muscle: effect of ageing. *Journal of the Neurological Sciences*, **1992**, 113, 91-8	3.2	294
347	Mitochondrial respiratory chain disorders I: mitochondrial DNA defects. *Lancet, The*, **2000**, 355, 299-304	40	288
346	Mitochondrial myopathies: clinical and biochemical features of 30 patients with major deletions of muscle mitochondrial DNA. *Annals of Neurology*, **1989**, 26, 699-708	9.4	287
345	Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. *Movement Disorders*, **2014**, 29, 1476-85	7	286
344	Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. *Lancet, The*, **2014**, 384, 545-55	40	285
343	Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease. *Journal of Neurochemistry*, **1994**, 63, 1987-90	6	282

342	Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. *Annals of Neurology*, **1998**, 44, 177-86	9.4	278
341	The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: an international study using the nonmotor symptoms questionnaire. *Movement Disorders*, **2010**, 25, 704-9	7	266
340	Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. *Human Molecular Genetics*, **2000**, 9, 275-82	5.6	262
339	New insights into the cause of Parkinson's disease. *Neurology*, **1992**, 42, 2241-50	6.5	257
338	Genetic and environmental factors in the cause of Parkinson's disease. *Annals of Neurology*, **2003**, 53 Suppl 3, S16-23; discussion S23-5	9.4	254
337	Novel pharmacological targets for the treatment of Parkinson's disease. *Nature Reviews Drug Discovery*, **2006**, 5, 845-54	64.1	229
336	Mitochondria and degenerative disorders. *American Journal of Medical Genetics Part A*, **2001**, 106, 27-36		229
335	Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. *Biochimica Et Biophysica Acta - Bioenergetics*, **1999**, 1410, 159-70	4.6	229
334	Mitochondria and quality control defects in a mouse model of Gaucher disease--links to Parkinson's disease. *Cell Metabolism*, **2013**, 17, 941-953	24.6	228
333	Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group. *Annals of Neurology*, **1992**, 32 Suppl, S94-100	9.4	226
332	Complex I, iron, and ferritin in Parkinson's disease substantia nigra. *Annals of Neurology*, **1994**, 36, 876-81	9.4	210
331	Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease. *Brain*, **2017**, 140, 3191-3203	11.2	209
330	Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. *JAMA - Journal of the American Medical Association*, **2004**, 291, 358-64	27.4	204
329	Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. *Brain*, **2014**, 137, 1481-95	11.2	201
328	Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. *Archives of Neurology*, **2005**, 62, 621-6		185
327	Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. *Movement Disorders*, **2007**, 22, 2398-404	7	174
326	Evidence for mitochondrial dysfunction in Parkinson's disease--a critical appraisal. *Movement Disorders*, **1994**, 9, 125-38	7	174
325	Neurobiology and treatment of Parkinson's disease. *Trends in Pharmacological Sciences*, **2009**, 30, 41-7	13.2	168

324	Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. *Human Molecular Genetics*, **2000**, 9, 2683-9	5.6	166
323	Mitochondria in the etiology and pathogenesis of Parkinson's disease. *Annals of Neurology*, **1998**, 44, S89-98	9.4	165
322	Mitochondrial respiratory chain disorders II: neurodegenerative disorders and nuclear gene defects. *Lancet, The*, **2000**, 355, 389-94	40	162
321	Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors. *Brain Research*, **1997**, 777, 110-8	3.7	158
320	Timing of treatment initiation in Parkinson's disease: a need for reappraisal?. *Annals of Neurology*, **2006**, 59, 559-62	9.4	157
319	Mitochondrial dysfunction in neurodegenerative disorders. *Biochimica Et Biophysica Acta - Bioenergetics*, **1998**, 1366, 225-33	4.6	149
318	Silencing of PINK1 expression affects mitochondrial DNA and oxidative phosphorylation in dopaminergic cells. *PLoS ONE*, **2009**, 4, e4756	3.7	147
317	TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. *Lancet Neurology, The*, **2006**, 5, 1013-20	24.1	144
316	Continuous dopamine-receptor stimulation in early Parkinson's disease. *Trends in Neurosciences*, **2000**, 23, S117-26	13.3	144
315	Etiology of Parkinson's disease. *Neurology*, **2006**, 66, S10-23	6.5	143
314	Glucocerebrosidase and Parkinson disease: Recent advances. *Molecular and Cellular Neurosciences*, **2015**, 66, 37-42	4.8	142
313	Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort. *JAMA Neurology*, **2015**, 72, 201-8	17.2	139
312	Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. *Lancet Neurology, The*, **2013**, 12, 747-55	24.1	139
311	Leber's hereditary optic neuropathy (LHON) pathogenic mutations induce mitochondrial-dependent apoptotic death in transmitochondrial cells incubated with galactose medium. *Journal of Biological Chemistry*, **2003**, 278, 4145-50	5.4	139
310	Molecular and clinical prodrome of Parkinson disease: implications for treatment. *Nature Reviews Neurology*, **2010**, 6, 309-17	15	132
309	PRRT2 gene mutations: from paroxysmal dyskinesia to episodic ataxia and hemiplegic migraine. *Neurology*, **2012**, 79, 2115-21	6.5	132
308	Human complex I defects in neurodegenerative diseases. *Biochimica Et Biophysica Acta - Bioenergetics*, **1998**, 1364, 261-70	4.6	132
307	Science, medicine, and the future: Parkinson's disease. *BMJ: British Medical Journal*, **1999**, 318, 311-4		131

306	Severe impairment of complex I-driven adenosine triphosphate synthesis in leber hereditary optic neuropathy cybrids. *Archives of Neurology*, **2005**, 62, 730-6		129
305	G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization. *Human Molecular Genetics*, **2012**, 21, 4201-13	5.6	128
304	Waking up to sleep episodes in Parkinson's disease. *Movement Disorders*, **2000**, 15, 212-5	7	128
303	Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. *Journal of the Neurological Sciences*, **1998**, 158, 24-9	3.2	127
302	Sleep attacks (sleep episodes) with pergolide. *Lancet, The*, **2000**, 355, 1332-3	40	126
301	Cytochrome c oxidase deficiency associated with the first stop-codon point mutation in human mtDNA. *American Journal of Human Genetics*, **1998**, 63, 29-36	11	124
300	Oxidative stress and Parkinson's disease. *Annals of the New York Academy of Sciences*, **1996**, 786, 217-23	6.5	122
299	Mitochondrial and lysosomal biogenesis are activated following PINK1/parkin-mediated mitophagy. *Journal of Neurochemistry*, **2016**, 136, 388-402	6	120
298	A missense mutation of cytochrome oxidase subunit II causes defective assembly and myopathy. *American Journal of Human Genetics*, **1999**, 65, 1030-9	11	120
297	The relationship between glucocerebrosidase mutations and Parkinson disease. *Journal of Neurochemistry*, **2016**, 139 Suppl 1, 77-90	6	118
296	Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. *JAMA Neurology*, **2017**, 74, 216-224	17.2	116
295	Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease. *Human Molecular Genetics*, **2016**, 25, 3432-3445	5.6	114
294	Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. *Annals of Neurology*, **2000**, 47, 80-6	9.4	114
293	Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial. *JAMA Neurology*, **2020**, 77, 427-434	17.2	113
292	Molecular mechanisms in mitochondrial DNA depletion syndrome. *Human Molecular Genetics*, **1997**, 6, 935-42	5.6	112
291	Ambroxol effects in glucocerebrosidase and □synuclein transgenic mice. *Annals of Neurology*, **2016**, 80, 766-775	9.4	109
290	Mitochondrial function and parental sex effect in Huntington's disease. *Lancet, The*, **1990**, 336, 749	40	109
289	Mutant Parkin impairs mitochondrial function and morphology in human fibroblasts. *PLoS ONE*, **2010**, 5, e12962	3.7	104

288	Oxidative-phosphorylation defects in liver of patients with Wilson's disease. *Lancet, The*, **2000**, 356, 469-74	44	104
287	PINK1 disables the anti-fission machinery to segregate damaged mitochondria for mitophagy. *Journal of Cell Biology*, **2016**, 213, 163-71	7.3	104
286	Treatment options in the modern management of Parkinson disease. *Archives of Neurology*, **2007**, 64, 1083-8		100
285	Therapeutic prospects for Parkinson disease. *Annals of Neurology*, **2013**, 74, 337-47	9.4	99
284	Mitochondrial DNA analysis in Parkinson's disease. *Movement Disorders*, **1990**, 5, 294-7	7	97
283	A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. *Human Molecular Genetics*, **2013**, 22, 1039-49	5.6	96
282	Liver failure associated with mitochondrial DNA depletion. *Journal of Hepatology*, **1998**, 28, 556-63	13.4	95
281	Cells bearing mutations causing Leber's hereditary optic neuropathy are sensitized to Fas-Induced apoptosis. *Journal of Biological Chemistry*, **2002**, 277, 5810-5	5.4	95
280	Synuclein and mitochondrial dysfunction in Parkinson's disease. *Molecular Neurobiology*, **2013**, 47, 587-97	6.2	93
279	Cyclosporin inhibition of apoptosis induced by mitochondrial complex I toxins. *Brain Research*, **1998**, 809, 12-7	3.7	93
278	Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects. *CNS Drugs*, **2011**, 25, 1061-71	6.7	92
277	Oxidative stress and mitochondrial dysfunction in neurodegeneration. *Current Opinion in Neurology*, **1996**, 9, 260-4	7.1	92
276	Nuclear complementation restores mtDNA levels in cultured cells from a patient with mtDNA depletion. *American Journal of Human Genetics*, **1993**, 53, 663-9	11	91
275	Why have we failed to achieve neuroprotection in Parkinson's disease?. *Annals of Neurology*, **2008**, 64 Suppl 2, S101-10	9.4	89
274	Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. *Annals of Medicine*, **2013**, 45, 511-21	1.5	88
273	Leber hereditary optic neuropathy mtDNA mutations disrupt glutamate transport in cybrid cell lines. *Brain*, **2004**, 127, 2183-92	11.2	88
272	A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. *Movement Disorders*, **2012**, 27, 106-12	7	87
271	No evidence for substrate accumulation in Parkinson brains with GBA mutations. *Movement Disorders*, **2015**, 30, 1085-9	7	86

270	Mitochondrial dysfunction associated with neuronal death following status epilepticus in rat. *Epilepsy Research*, **2002**, 48, 157-68	3	86
269	Mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson's Disease Research Group. *Annals of Neurology*, **1992**, 32 Suppl, S116-24	9.4	85
268	Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models. *Scientific Reports*, **2016**, 6, 31380	4.9	83
267	Etiology and pathogenesis of Parkinson disease. *Neurologic Clinics*, **2009**, 27, 583-603, v	4.5	83
266	Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. *Journal of Neurochemistry*, **2004**, 91, 1075-81	6	83
265	In vivo skeletal muscle mitochondrial function in Leber's hereditary optic neuropathy assessed by 31P magnetic resonance spectroscopy. *Annals of Neurology*, **1997**, 42, 573-9	9.4	81
264	Hyposmia and cognitive impairment in Gaucher disease patients and carriers. *Movement Disorders*, **2012**, 27, 526-32	7	80
263	Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. *Annals of Neurology*, **2006**, 60, 253-5	9.4	79
262	Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. *Neurology*, **2011**, 77, 767-74	6.5	78
261	Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson's disease pathogenesis. *Journal of Neurochemistry*, **2009**, 110, 1005-13	6	77
260	A clinical and family history study of Parkinson's disease in heterozygous glucocerebrosidase mutation carriers. *Journal of Neurology, Neurosurgery and Psychiatry*, **2012**, 83, 853-4	5.5	76
259	Oxidative stress in Parkinson's disease. *Neuropathology and Applied Neurobiology*, **1995**, 21, 3-9	5.2	76
258	Recent developments in biomarkers in Parkinson disease. *Current Opinion in Neurology*, **2013**, 26, 395-400	7.1	75
257	Mitochondrial contribution to Parkinson's disease pathogenesis. *Parkinson's Disease*, **2011**, 2011, 159160	2.6	75
256	Clinical correlates of mitochondrial function in Huntington's disease muscle. *Movement Disorders*, **2007**, 22, 1715-21	7	74
255	A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need. *PLoS ONE*, **2013**, 8, e57221	3.7	73
254	Restless legs syndrome: an update on treatment options. *Drugs*, **2004**, 64, 149-58	12.1	73
253	Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: an in vivo 31P magnetic resonance spectroscopy study. *Cardiovascular Research*, **2001**, 52, 111-9	9.9	73

252	Glucocerebrosidase 1 deficient Danio rerio mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death. *Human Molecular Genetics*, **2015**, 24, 6640-52	5.6	72
251	Genetic and clinical heterogeneity in paroxysmal kinesigenic dyskinesia: evidence for a third EKD gene. *Movement Disorders*, **2002**, 17, 717-25	7	72
250	Platelet mitochondrial function in Leber's hereditary optic neuropathy. *Journal of the Neurological Sciences*, **1994**, 122, 80-3	3.2	72
249	Quantitation of a mitochondrial DNA deletion in Parkinson's disease. *FEBS Letters*, **1992**, 299, 218-22	3.8	71
248	The role of glucocerebrosidase in Parkinson disease pathogenesis. *FEBS Journal*, **2018**, 285, 3591-3603	5.7	70
247	Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson's disease. *Brain Research*, **1993**, 627, 349-53	3.7	70
246	Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. *Movement Disorders*, **2010**, 25, 2542-9	7	69
245	The influence of nuclear background on the biochemical expression of 3460 Leber's hereditary optic neuropathy. *Annals of Neurology*, **1998**, 44, 187-93	9.4	68
244	Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate. *Synapse*, **2017**, 71, e21967	2.4	67
243	Complex I function in familial and sporadic dystonia. *Annals of Neurology*, **1997**, 41, 556-9	9.4	67
242	PINK1-parkin-dependent mitophagy involves ubiquitination of mitofusins 1 and 2: Implications for Parkinson disease pathogenesis. *Autophagy*, **2011**, 7, 243-5	10.2	66
241	Molecular defects of NADH-ubiquinone oxidoreductase (complex I) in mitochondrial diseases. *Journal of Bioenergetics and Biomembranes*, **1988**, 20, 365-82	3.7	66
240	Mitochondrial dysfunction in glaucoma: understanding genetic influences. *Mitochondrion*, **2012**, 12, 202-12	4.9	64
239	Friedreich's ataxia: from disease mechanisms to therapeutic interventions. *Antioxidants and Redox Signaling*, **2006**, 8, 438-43	8.4	64
238	Pathogenic mechanisms of neurodegeneration in Parkinson disease. *Neurologic Clinics*, **2015**, 33, 1-17	4.5	63
237	Visual short-term memory deficits associated with GBA mutation and Parkinson's disease. *Brain*, **2014**, 137, 2303-11	11.2	63
236	Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation. *Molecular Neurodegeneration*, **2015**, 10, 41	19	62
235	Mitochondrial respiratory chain function in multiple system atrophy. *Movement Disorders*, **1997**, 12, 418-22	7	62

234	Smoking and mitochondrial function: a model for environmental toxins. *QJM - Monthly Journal of the Association of Physicians*, **1993**, 86, 657-60	2.7	62
233	Molecular basis of mitochondrial myopathies: polypeptide analysis in complex-I deficiency. *Lancet, The*, **1988**, 1, 500-3	40	62
232	Neuroprotection and dopamine agonists. *Neurology*, **2002**, 58, S9-18	6.5	62
231	Mitochondrial dysfunction associated with glucocerebrosidase deficiency. *Neurobiology of Disease*, **2016**, 90, 43-50	7.5	61
230	The genetics of Parkinson's disease. *British Medical Bulletin*, **2015**, 114, 39-52	5.4	61
229	International Cooperative Ataxia Rating Scale (ICARS): appropriate for studies of Friedreich's ataxia?. *Movement Disorders*, **2005**, 20, 1585-91	7	61
228	Recharging mitochondrial batteries in old eyes. Near infra-red increases ATP. *Experimental Eye Research*, **2014**, 122, 50-3	3.7	60
227	Central role and mechanisms of β-cell dysfunction and death in friedreich ataxia-associated diabetes. *Annals of Neurology*, **2012**, 72, 971-82	9.4	60
226	Glucocerebrosidase and Parkinson Disease: Molecular, Clinical, and Therapeutic Implications. *Neuroscientist*, **2018**, 24, 540-559	7.6	59
225	Successful outcome of progressive multifocal leukoencephalopathy with cytarabine and interferon. *Annals of Neurology*, **1993**, 33, 407-11	9.4	59
224	Molecular changes in the postmortem parkinsonian brain. *Journal of Neurochemistry*, **2016**, 139 Suppl 1, 27-58	6	59
223	Disease modification in Parkinson's disease. *Lancet Neurology, The*, **2004**, 3, 362-8	24.1	58
222	A 31P magnetic resonance spectroscopy study of mitochondrial function in skeletal muscle of patients with Parkinson's disease. *Journal of the Neurological Sciences*, **1994**, 125, 77-81	3.2	58
221	Functional consequences of the 3460-bp mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. *Journal of the Neurological Sciences*, **1999**, 165, 10-7	3.2	57
220	Mitochondrial pathology in Parkinson's disease. *Mount Sinai Journal of Medicine*, **2011**, 78, 872-81		56
219	A new family with paroxysmal exercise induced dystonia and migraine: a clinical and genetic study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2000**, 68, 609-14	5.5	56
218	Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. *Neurology*, **2009**, 72, S44-50	6.5	55
217	Mitochondrial DNA (mtDNA) diseases: correlation of genotype to phenotype. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **1995**, 1271, 135-40	6.9	55

216	Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. *Annals of Neurology*, **2001**, 49, 590-6	9.4	55
215	Non-motor outcomes depend on location of neurostimulation in Parkinson's disease. *Brain*, **2019**, 142, 3592-3604	11.2	54
214	PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease. *Movement Disorders*, **2011**, 26, 1259-65	7	54
213	Mitochondrial dysfunction in neurodegenerative diseases. *Neurochemical Research*, **2008**, 33, 2502-9	4.6	54
212	End-of-dose wearing off in Parkinson disease: a 9-question survey assessment. *Clinical Neuropharmacology*, **2006**, 29, 312-21	1.4	54
211	Timing of deep brain stimulation in Parkinson disease: a need for reappraisal?. *Annals of Neurology*, **2013**, 73, 565-75	9.4	53
210	Perspectives on recent advances in the understanding and treatment of Parkinson's disease. *European Journal of Neurology*, **2009**, 16, 1090-9	6	53
209	Detection of nitrosyl complexes in human substantia nigra, in relation to Parkinson's disease. *Biochemical and Biophysical Research Communications*, **1996**, 228, 298-305	3.4	52
208	The H50Q mutation induces a 10-fold decrease in the solubility of □synuclein. *Journal of Biological Chemistry*, **2015**, 290, 2395-404	5.4	51
207	Neuroprotection for Parkinson's disease: prospects and promises. *Annals of Neurology*, **2003**, 53 Suppl 3, S1-2	9.4	51
206	Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons. *Scientific Reports*, **2018**, 8, 1385	4.9	50
205	Mitochondrial myopathy with a defect of mitochondrial-protein transport. *New England Journal of Medicine*, **1990**, 323, 37-42	59.2	50
204	Mitochondrial dysfunction in neurodegeneration. *Journal of Bioenergetics and Biomembranes*, **1997**, 29, 175-83	3.7	49
203	Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells. *Neuropharmacology*, **2004**, 46, 562-9	5.5	49
202	Clinical, biochemical and molecular genetic features of Leber's hereditary optic neuropathy. *Biochimica Et Biophysica Acta - Bioenergetics*, **1999**, 1410, 147-58	4.6	48
201	The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 1. *American Journal of Neuroradiology*, **2015**, 36, 229-35	4.4	46
200	Dopaminergic neuronal imaging in genetic Parkinson's disease: insights into pathogenesis. *PLoS ONE*, **2013**, 8, e69190	3.7	46
199	Analysis of mutant DNA polymerase gamma in patients with mitochondrial DNA depletion. *Human Mutation*, **2009**, 30, 248-54	4.7	46

198	Clinical prodromes of neurodegeneration in Anderson-Fabry disease. *Neurology*, **2015**, 84, 1454-64	6.5	45
197	Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 3214-5	11.5	45
196	Mitochondrial DNA depletion syndrome is expressed in amniotic fluid cell cultures. *American Journal of Pathology*, **1999**, 155, 67-70	5.8	45
195	Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine. *Movement Disorders*, **2019**, 34, 9-21	7	45
194	Mitochondrial DNA mutation underlying Leigh's syndrome: clinical, pathological, biochemical, and genetic studies of a patient presenting with progressive myoclonic epilepsy. *Journal of the Neurological Sciences*, **1994**, 121, 57-65	3.2	44
193	Mitochondrial function in neurodegeneration and ageing. *Mutation Research - DNAging*, **1992**, 275, 133-43		43
192	Mitochondrial complex I deficiency in Parkinson's disease. *Advances in Neurology*, **1993**, 60, 288-91		43
191	A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers. *Stem Cell Reports*, **2017**, 8, 728-742	8	42
190	Targeting mitochondria for neuroprotection in Parkinson's disease. *Antioxidants and Redox Signaling*, **2012**, 16, 965-73	8.4	42
189	Isolation of transcriptomal changes attributable to LHON mutations and the cybridization process. *Brain*, **2005**, 128, 1026-37	11.2	42
188	Somatic copy number gains of □synuclein (SNCA) in Parkinson's disease and multiple system atrophy brains. *Brain*, **2018**, 141, 2419-2431	11.2	41
187	Mitochondrial impairment increases FL-PINK1 levels by calcium-dependent gene expression. *Neurobiology of Disease*, **2014**, 62, 426-40	7.5	41
186	The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease. *Movement Disorders*, **2008**, 23 Suppl 3, S515-20	7	41
185	Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. *Annals of Neurology*, **2003**, 53 Suppl 3, S149-57; discussion S157-9	9.4	41
184	Indices of oxidative stress in Parkinson's disease, Alzheimer's disease and dementia with Lewy bodies. *Journal of Neural Transmission Supplementum*, **1997**, 51, 167-73		39
183	Anaesthetics increase light emission from aequorin at constant ionised calcium. *Nature*, **1980**, 284, 168-9	50.4	39
182	The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 2. *American Journal of Neuroradiology*, **2015**, 36, 236-44	4.4	37
181	Cytochrome oxidase immunohistochemistry: clues for genetic mechanisms. *Brain*, **2000**, 123 Pt 3, 591-600	11.2	37

180	Free radicals and mitochondrial dysfunction in Parkinson's disease. *Biochemical Society Transactions* , **1993**, 21, 367-70	5.1	37
179	L-dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain. *Movement Disorders*, **1995**, 10, 295-7	7	37
178	Safinamide in the treatment of Parkinson's disease. *Expert Opinion on Pharmacotherapy*, **2010**, 11, 2261-8	4	36
177	Creation of an open-access, mutation-defined fibroblast resource for neurological disease research. *PLoS ONE*, **2012**, 7, e43099	3.7	35
176	Analysis of the trinucleotide CAG repeat from the DNA polymerase gamma gene (POLG) in patients with Parkinson's disease. *Neuroscience Letters*, **2005**, 376, 56-9	3.3	35
175	Salbutamol treatment in a patient with hyperkalaemic periodic paralysis due to a mutation in the skeletal muscle sodium channel gene (SCN4A). *Journal of Neurology, Neurosurgery and Psychiatry*, **1998**, 65, 248-50	5.5	35
174	Evaluation of the detection of GBA missense mutations and other variants using the Oxford Nanopore MinION. *Molecular Genetics & Genomic Medicine*, **2019**, 7, e564	2.3	35
173	Insights into the structural biology of Gaucher disease. *Experimental Neurology*, **2017**, 298, 180-190	5.7	34
172	The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice. *Brain*, **2017**, 140, 2706-2721	11.2	34
171	Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study. *Movement Disorders*, **2010**, 25, 1627-32	7	34
170	Normal in vivo skeletal muscle oxidative metabolism in sporadic inclusion body myositis assessed by 31P-magnetic resonance spectroscopy. *Brain*, **1998**, 121 (Pt 11), 2119-26	11.2	33
169	Secondary abnormalities of mitochondrial DNA associated with neurodegeneration. *Biochemical Society Symposia*, **1999**, 66, 99-110		32
168	Calcium dysregulation in Parkinson's disease. *Brain*, **2013**, 136, 2015-6	11.2	31
167	Resistance to the most common optic neuropathy is associated with systemic mitochondrial efficiency. *Neurobiology of Disease*, **2015**, 82, 78-85	7.5	31
166	A clinical and genetic study of SPG5A linked autosomal recessive hereditary spastic paraplegia. *Neurology*, **2003**, 61, 235-8	6.5	31
165	Mitochondrial myopathies and encephalomyopathies. *European Journal of Clinical Investigation*, **1999**, 29, 886-98	4.6	31
164	Respiratory-deficient human fibroblasts exhibiting defective mitochondrial DNA replication. *Biochemical Journal*, **1995**, 305 (Pt 3), 817-22	3.8	31
163	Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease. *Movement Disorders*, **2010**, 25, 2326-32	7	30

162	Hunting for genes in essential tremor. *European Journal of Neurology*, **2008**, 15, 889-90	6	30
161	Dopamine agonists in Parkinson's disease. *Expert Review of Neurotherapeutics*, **2008**, 8, 671-7	4.3	30
160	Pathogenesis of Parkinson's disease. *Baillière's Clinical Neurology*, **1997**, 6, 15-36		30
159	Evolution of prodromal parkinsonian features in a cohort of mutation-positive individuals: a 6-year longitudinal study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 1091-1097	5.5	29
158	Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial. *Clinical Neuropharmacology*, **2012**, 35, 174-81	1.4	29
157	Analysis of the factors influencing the cardiac phenotype in Friedreich's ataxia. *Movement Disorders*, **2010**, 25, 846-52	7	29
156	Diagnosing restless legs syndrome (RLS) in primary care. *Current Medical Research and Opinion*, **2004**, 20, 1785-95	2.5	29
155	The 14484 ND6 mtDNA mutation in Leber hereditary optic neuropathy does not affect fibroblast complex I activity. *American Journal of Human Genetics*, **1995**, 57, 1501-2	11	29
154	Mitochondrial function in Alzheimer's disease. *Lancet, The*, **1993**, 341, 969-70	40	28
153	Human mitochondrial complex I dysfunction. *Biochimica Et Biophysica Acta - Bioenergetics*, **1992**, 1101, 198-203	4.6	28
152	Glucocerebrosidase in Parkinson's disease: Insights into pathogenesis and prospects for treatment. *Movement Disorders*, **2016**, 31, 830-5	7	28
151	Meclizine-induced enhanced glycolysis is neuroprotective in Parkinson disease cell models. *Scientific Reports*, **2016**, 6, 25344	4.9	27
150	Antibodies to human optic nerve in Leber's hereditary optic neuropathy. *Journal of the Neurological Sciences*, **1995**, 130, 134-8	3.2	27
149	Excessive daytime sleepiness in Parkinson's disease. *Neurology*, **2004**, 63, S24-7	6.5	26
148	□Synuclein structural features inhibit harmful polyunsaturated fatty acid oxidation, suggesting roles in neuroprotection. *Journal of Biological Chemistry*, **2017**, 292, 6927-6937	5.4	25
147	Practical recommendations for the process of proposing, planning and writing a neurological management guideline by EAN task forces. *European Journal of Neurology*, **2015**, 22, 1505-10	6	25
146	Drug selection and timing of initiation of treatment in early Parkinson's disease. *Annals of Neurology*, **2008**, 64 Suppl 2, S47-55	9.4	25
145	Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis. *European Journal of Neurology*, **2009**, 16, 1305-11	6	25

144	Sensitivity of respiratory chain activities to lipid peroxidation: effect of vitamin E deficiency. *Biochemical Journal*, **2001**, 357, 887-892	3.8	25
143	Proximal myotonic myopathy (PROMM) presenting as myotonia during pregnancy. *Neuromuscular Disorders*, **1999**, 9, 144-9	2.9	25
142	A mitochondrial encephalomyopathy with specific deficiencies of two respiratory chain polypeptides and a circulating autoantibody to a mitochondrial matrix protein. *Brain*, **1990**, 113 (Pt 2), 419-32	11.2	25
141	Retinal thinning in Gaucher disease patients and carriers: results of a pilot study. *Molecular Genetics and Metabolism*, **2013**, 109, 221-3	3.7	24
140	Characterization of a novel TYMP splice site mutation associated with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). *Neuromuscular Disorders*, **2009**, 19, 151-4	2.9	24
139	Future directions in the treatment of Parkinson's disease. *Movement Disorders*, **2007**, 22 Suppl 17, S385-91	7	24
138	Mitochondrial dysfunction in neurodegenerative disorders and ageing. *Advances in Experimental Medicine and Biology*, **2001**, 487, 229-51	3.6	23
137	Mitochondrial DNA mutations and mitochondrial dysfunction in epilepsy. *Epilepsia*, **1999**, 40 Suppl 3, 33-40	6.4	23
136	The role of the alpha-synuclein gene mutation in patients with sporadic Parkinson's disease in the United Kingdom. *Journal of Neurology, Neurosurgery and Psychiatry*, **1998**, 65, 378-9	5.5	22
135	The molecular pathology of respiratory-chain dysfunction in human mitochondrial myopathies. *Biochimica Et Biophysica Acta - Bioenergetics*, **1990**, 1018, 217-22	4.6	22
134	Investigation of somatic CNVs in brains of synucleinopathy cases using targeted SNCA analysis and single cell sequencing. *Acta Neuropathologica Communications*, **2019**, 7, 219	7.3	22
133	Aetiopathogenesis of Parkinson's disease. *Journal of Neurology*, **2011**, 258, S307-10	5.5	21
132	Mitochondrial myopathies: genetic defects. *Biochemical Society Transactions*, **1990**, 18, 519-22	5.1	21
131	Myopathy in vitamin E deficient rats: muscle fibre necrosis associated with disturbances of mitochondrial function. *Journal of Anatomy*, **1993**, 183 (Pt 3), 451-61	2.9	21
130	Chaperone-mediated autophagy as a therapeutic target for Parkinson disease. *Expert Opinion on Therapeutic Targets*, **2018**, 22, 823-832	6.4	21
129	Coordinating outcomes measurement in ataxia research: do some widely used generic rating scales tick the boxes?. *Movement Disorders*, **2006**, 21, 1396-403	7	20
128	Causes of neuronal death in Parkinson's disease. *Advances in Neurology*, **2001**, 86, 155-62		20
127	Evolution and clustering of prodromal parkinsonian features in GBA1 carriers. *Movement Disorders*, **2019**, 34, 1365-1373	7	19

126	Nonmotor Symptoms in Experimental Models of Parkinson's Disease. *International Review of Neurobiology*, **2017**, 133, 63-89	4.4	19
125	Assessment of in vitro and in vivo mitochondrial function in Friedreich's ataxia and Huntington's disease. *Methods in Molecular Biology*, **2004**, 277, 293-307	1.4	19
124	Updated guidelines for the management of Parkinson's disease. *British Journal of Hospital Medicine*, **2001**, 62, 456-70		19
123	Mitochondrial disorders. *Current Opinion in Neurology*, **2000**, 13, 527-32	7.1	19
122	A case of mitochondrial myopathy, lactic acidosis and complex I deficiency. *Journal of Neurology*, **1990**, 237, 399-404	5.5	19
121	Brain Microglial Activation Increased in Glucocerebrosidase (GBA) Mutation Carriers without Parkinson's disease. *Movement Disorders*, **2021**, 36, 774-779	7	19
120	Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's disease. *European Journal of Neurology*, **2013**, 20, 50-6	6	18
119	Inborn and induced defects of mitochondria. *Archives of Neurology*, **1998**, 55, 1293-6		18
118	Nuclear and mitochondrial genetics in Parkinson's disease. *Journal of Medical Genetics*, **1995**, 32, 411-4	5.8	18
117	Glucocerebrosidase activity, cathepsin D and monomeric □synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation. *Neurobiology of Disease*, **2020**, 134, 104620	7.5	18
116	Etiopathogenesis and treatment of Parkinson's disease. *Current Topics in Medicinal Chemistry*, **2009**, 9, 860-8	3	18
115	Two pregnant women with vomiting and fits. *American Journal of Obstetrics and Gynecology*, **1997**, 177, 1539-40	6.4	17
114	Mitochondrial disorders: an overview. *Journal of Bioenergetics and Biomembranes*, **1997**, 29, 105-7	3.7	17
113	Mitochondrial disorders. *Current Opinion in Genetics and Development*, **1993**, 3, 457-65	4.9	17
112	Protection against paraquat and A53T alpha-synuclein toxicity by cabergoline is partially mediated by dopamine receptors. *Journal of the Neurological Sciences*, **2009**, 278, 44-53	3.2	16
111	MitBASE : a comprehensive and integrated mitochondrial DNA database. The present status. *Nucleic Acids Research*, **2000**, 28, 148-52	20.1	16
110	Nitric oxide enhances MPP(+) inhibition of complex I. *FEBS Letters*, **2001**, 504, 50-2	3.8	16
109	Glucocerebrosidase deficiency promotes release of □synuclein fibrils from cultured neurons. *Human Molecular Genetics*, **2020**, 29, 1716-1728	5.6	15

108	Friedreich's ataxia impact scale: a new measure striving to provide the flexibility required by today's studies. *Movement Disorders*, **2009**, 24, 984-92	7	15
107	Sensitivity of respiratory chain activities to lipid peroxidation: effect of vitamin E deficiency. *Biochemical Journal*, **2001**, 357, 887-92	3.8	15
106	Immunological phenotyping of fibroblast cultures from patients with a mitochondrial respiratory chain deficit. *Laboratory Investigation*, **2001**, 81, 1069-77	5.9	15
105	MitBASE: a comprehensive and integrated mitochondrial DNA database. *Nucleic Acids Research*, **1999**, 27, 128-33	20.1	15
104	Two-dimensional protein mapping by gold stain and immunoblotting. *Analytical Biochemistry*, **1988**, 169, 167-71	3.1	15
103	The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease. *Neurology*, **2000**, 55, S65-8; discussion S69-71	6.5	15
102	Mitochondrial DNA in focal dystonia: a cybrid analysis. *Annals of Neurology*, **1998**, 44, 258-61	9.4	14
101	Metabolic enzyme expression in dopaminergic neurons in Parkinson's disease: an in situ hybridization study. *Annals of Neurology*, **2001**, 50, 142-9	9.4	14
100	Mitochondrial dysfunction in friedreich's ataxia. *NeuroSignals*, **2001**, 10, 263-70	1.9	14
99	Pramipexole reduces phosphorylation of ⊟synuclein at serine-129. *Journal of Molecular Neuroscience*, **2013**, 51, 573-80	3.3	13
98	DJ-1 is a redox sensitive adapter protein for high molecular weight complexes involved in regulation of catecholamine homeostasis. *Human Molecular Genetics*, **2017**, 26, 4028-4041	5.6	13
97	Mitochondrial myopathies: clinical defects. *Biochemical Society Transactions*, **1990**, 18, 523-6	5.1	13
96	Biochemical and molecular aspects of human mitochondrial respiratory chain disorders. *Biochemical Society Transactions*, **1990**, 18, 517-9	5.1	13
95	Neuroprotection in Parkinson's disease. *Parkinsonism and Related Disorders*, **2009**, 15 Suppl 4, S41-3	3.6	12
94	Ablation of the pro-inflammatory master regulator miR-155 does not mitigate neuroinflammation or neurodegeneration in a vertebrate model of Gaucher's disease. *Neurobiology of Disease*, **2019**, 127, 563-569	7.5	11
93	Early versus delayed initiation of pharmacotherapy in Parkinson's disease. *Drugs*, **2014**, 74, 645-57	12.1	11
92	Neuromyelitis optica (Devic's syndrome): no association with the primary mitochondrial DNA mutations found in Leber hereditary optic neuropathy. *Journal of Neurology, Neurosurgery and Psychiatry*, **1997**, 62, 85-7	5.5	11
91	HLA class II genotypes in Leber's hereditary optic neuropathy. *Journal of the Neurological Sciences*, **1994**, 126, 193-6	3.2	11

90	Mitochondrial myopathies. *BMJ: British Medical Journal*, **1989**, 298, 1127-8		11
89	Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats. *Neurobiology of Disease*, **2014**, 64, 36-47	7.5	10
88	Movement disorders: advances in cause and treatment. *Lancet Neurology, The*, **2010**, 9, 6-7	24.1	10
87	Summary of GIGYF2 studies in Parkinson's disease: the burden of proof. *European Journal of Neurology*, **2010**, 17, 175-6	6	10
86	Mitochondrial disorders. *Current Opinion in Neurology*, **1997**, 10, 43-7	7.1	10
85	Role of the pharmacist in the effective management of wearing-off in Parkinson's disease. *Annals of Pharmacotherapy*, **2007**, 41, 1842-9	2.9	10
84	Sporadic inclusion body myositis not linked to prion protein codon 129 methionine homozygosity. *Neurology*, **2000**, 55, 1235	6.5	10
83	Guidelines for the management of Parkinson's disease. The Parkinson's Disease Consensus Working Group. *British Journal of Hospital Medicine*, **1998**, 59, 469-80		10
82	Parkinsonism in patients with chronic hepatitis C treated with interferon-alpha2b: a report of two cases. *European Journal of Gastroenterology and Hepatology*, **2010**, 22, 628-31	2.2	9
81	Transient Horner's syndrome during lumbar epidural anaesthesia. *European Journal of Neurology*, **2008**, 15, 530-1	6	9
80	Rasagiline in neurodegeneration. *Experimental Neurology*, **2008**, 212, 255-7	5.7	9
79	Mitochondria in the aetiology and pathogenesis of Parkinson's disease. *Parkinsonism and Related Disorders*, **1999**, 5, 139-43	3.6	9
78	Mitochondrial cytopathies. *Current Opinion in Neurobiology*, **1993**, 3, 760-7	7.6	9
77	Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease. *Npj Parkinson's Disease*, **2021**, 7, 48	9.7	9
76	The Cytomegalovirus protein pUL37 1 targets mitochondria to mediate neuroprotection. *Scientific Reports*, **2016**, 6, 31373	4.9	8
75	Mitochondrial DNA in idiopathic cardiomyopathy. *European Heart Journal*, **1998**, 19, 1725-9	9.5	8
74	Safinamide for the treatment of Parkinson's disease. *Expert Opinion on Pharmacotherapy*, **2017**, 18, 937-943	4	7
73	The biochemical basis of interactions between Glucocerebrosidase and alpha-synuclein in GBA1 mutation carriers. *Journal of Neurochemistry*, **2020**, 154, 11-24	6	7

72	Mitochondria in the etiology of Parkinson's disease. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2007**, 83, 479-91	3	7
71	Platelet aggregation in myotonia. *Journal of the Neurological Sciences*, **1985**, 71, 351-7	3.2	7
70	Vancomycin dose for pseudomembranous colitis. *Lancet, The*, **1980**, 2, 204	40	7
69	The gut-brain axis and Parkinson disease: clinical and pathogenetic relevance. *Annals of Medicine*, **2021**, 53, 611-625	1.5	7
68	Fits and strokes. *Lancet, The*, **2001**, 358, 120	40	6
67	Electron transport chain defects in Alzheimer's disease. *Neurology*, **1995**, 45, 599-600	6.5	6
66	L444P Gba1 mutation increases formation and spread of □synuclein deposits in mice injected with mouse □synuclein pre-formed fibrils. *PLoS ONE*, **2020**, 15, e0238075	3.7	6
65	Neurotoxicity and the mechanisms of cell death in Parkinson's disease. *Advances in Neurology*, **1996**, 69, 161-5		6
64	Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial.. *Journal of Parkinsonfs Disease*, **2021**,	5.3	6
63	Glucosylceramidase degradation in fibroblasts carrying bi-allelic Parkin mutations. *Molecular Genetics and Metabolism*, **2013**, 109, 402-3	3.7	5
62	Genetic counselling in mitochondrial diseases. *Current Opinion in Neurology*, **1997**, 10, 408-12	7.1	5
61	Timing the initiation of treatment in Parkinson's disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2008**, 79, 615	5.5	5
60	HLA class I genotypes in Leber's hereditary optic neuropathy. *Journal of the Neurological Sciences*, **1996**, 135, 173-5	3.2	5
59	Dorsal root ganglion proteins in Friedreich's ataxia. *Neuroscience Letters*, **1993**, 163, 182-4	3.3	5
58	Inborn and induced defects of the mitochondrial respiratory chain. *Biochemical Society Transactions*, **1994**, 22, 996-1001	5.1	5
57	MPTP and other Parkinson-inducing agents. *Current Opinion in Neurology and Neurosurgery*, **1992**, 5, 396-400		5
56	Exploring the Genotype-Phenotype Correlation in -Parkinson Disease: Clinical Aspects, Biomarkers, and Potential Modifiers. *Frontiers in Neurology*, **2021**, 12, 694764	4.1	5
55	Biofluid Biomarkers in Parkinson's Disease: Clarity Amid Controversy. *Movement Disorders*, **2020**, 35, 1128-1133	7	4

54	Enhancing the Activity of Glucocerebrosidase as a Treatment for Parkinson Disease. *CNS Drugs*, **2020**, 34, 915-923	6.7	4
53	Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. *Human Molecular Genetics*, **2013**, 22, 1697-1697	5.6	4
52	Relapsing neuropathy in an 18-year-old woman. *Lancet Neurology, The*, **2007**, 6, 192-8	24.1	4
51	One-step immunoaffinity purification of complex I subunits from beef heart mitochondria. *Protein Expression and Purification*, **1992**, 3, 223-7	2	4
50	Systemic PTEN-Akt1-mTOR pathway activity in patients with normal tension glaucoma and ocular hypertension: A case series. *Mitochondrion*, **2017**, 36, 96-102	4.9	3
49	A pragmatic, personalised approach to treatment initiation in Parkinson's disease. *Lancet Neurology, The*, **2020**, 19, 376-378	24.1	3
48	Novel pathogenic mutations in the glucocerebrosidase locus. *Molecular Genetics and Metabolism*, **2012**, 106, 495-7	3.7	3
47	Future strategies for neuroprotection in Parkinson's disease. *Neurodegenerative Diseases*, **2010**, 7, 210-22	2.3	3
46	Congenital muscular dystrophy with severe retrocollis and mental retardation: a report of two siblings. *Journal of Neurology, Neurosurgery and Psychiatry*, **1997**, 62, 279-81	5.5	3
45	Patterns of treatment for restless legs syndrome in primary care in the United Kingdom. *Clinical Therapeutics*, **2008**, 30, 405-18	3.5	3
44	Cardiac bioenergetics in Friedreich's ataxia. *Annals of Neurology*, **2003**, 54, 552; author reply 552-3	9.4	3
43	Update of the Human MitBASE database. *Nucleic Acids Research*, **1999**, 27, 143-6	20.1	3
42	Functional assessment of glucocerebrosidase modulator efficacy in primary patient-derived macrophages is essential for drug development and patient stratification. *Haematologica*, **2020**, 105, e206-e209	6.6	3
41	LRRK2 Parkinsonism: Does the Response to Gut Bacteria Mitigate the Neurological Picture?. *Movement Disorders*, **2021**, 36, 71-75	7	3
40	Mitochondrial DNA in Parkinson's disease. *Advances in Neurology*, **1999**, 80, 233-7		3
39	Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes. *Journal of Neurochemistry*, **2021**, 159, 826-839	6	2
38	Intronic Haplotypes in the GBA Gene Do Not Predict Age at Diagnosis of Parkinson's Disease. *Movement Disorders*, **2021**, 36, 1456-1460	7	2
37	Consensus on the treatment of dysphagia in Parkinson's disease. *Journal of the Neurological Sciences*, **2021**, 430, 120008	3.2	2

36	Ambroxol reverses tau and □synuclein accumulation in a cholinergic N370S GBA1 mutation model.. *Human Molecular Genetics*, **2022**,	5.6	2
35	Glucocerebrosidase Gene Mutation and Preclinical Markers of Parkinson Disease-Reply. *JAMA Neurology*, **2015**, 72, 724	17.2	1
34	Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. *Journal of Neurochemistry*, **2005**, 92, 215-215	6	1
33	Neurology. *Postgraduate Medical Journal*, **1991**, 67, 509-31	2	1
32	Colloidal gold staining and immunodetection in 2-d protein mapping. *Methods in Molecular Biology*, **1992**, 80, 255-9	1.4	1
31	Polypeptide and glycoprotein abnormalities in dorsal root ganglia of streptozotocin-diabetic rats. *Journal of the Neurological Sciences*, **1989**, 94, 147-61	3.2	1
30	Pseudomonas osteitis causing cranial nerve palsies. *Journal of Neurology, Neurosurgery and Psychiatry*, **1985**, 48, 1306-7	5.5	1
29	The mitochondrial myopathies. Defects of the mitochondrial respiratory chain and oxidative phosphorylation system. *Electroencephalography and Clinical Neurophysiology Supplement*, **1987**, 39, 103-14		1
28	Use of general practitioner computerised records to create a population based twin sample: pilot study based on Parkinson's disease. *BMJ: British Medical Journal*, **1997**, 315, 1510-1		1
27	The PINK1 □Parkin mitophagy signalling pathway is not functional in peripheral blood mononuclear cells		1
26	Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote □synuclein aggregation.. *Brain*, **2022**,	11.2	1
25	A multinational consensus on dysphagia in Parkinson's disease: screening, diagnosis and prognostic value. *Journal of Neurology*, **2021**, 1	5.5	1
24	Glucocerebrosidase mutations: A paradigm for neurodegeneration pathways. *Free Radical Biology and Medicine*, **2021**, 175, 42-55	7.8	1
23	Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments.. *Neurobiology of Disease*, **2022**, 105663	7.5	1
22	Pathogenetic insights into young-onset Parkinson disease. *Nature Reviews Neurology*, **2020**, 16, 245-246	15	0
21	Ropinirole 24-Hour Extended Release for Parkinson's Disease. *Aktuelle Neurologie*, **2007**, 34, 15-17		0
20	The PINK1-Parkin mitophagy signalling pathway is not functional in peripheral blood mononuclear cells. *PLoS ONE*, **2021**, 16, e0259903	3.7	0
19	Mitochondrial DNA and disease: What happens when things go wrong. *Biochemist*, **2005**, 27, 24-27	0.5	0

18	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. *Neurodegenerative Disease Management*, **2011**, 1, 441-443	2.8
17	Role of Mitochondria in Parkinson Disease and Huntington Disease. *Oxidative Stress and Disease*, **2012**, 415-431	
16	Treatment of Parkinson's Disease40-62	
15	MITOCHONDRIAL DNA AND DISEASE. *CONTINUUM Lifelong Learning in Neurology*, **2008**, 14, 133-148	3
14	2.IS.1. New treatment possibilities with oral Levodopa (Novartis Pharma AG/Orion Corporation). *Parkinsonism and Related Disorders*, **2007**, 13, S144-S145	3.6
13	Assessment of the significance of mitochondrial DNA damage by chemotherapeutic agents **2005**, 27, 337	
12	Disorders of the mitochondrial respiratory chain **2005**, 909-926	
11	Mitochondria: Aspects for neuroprotection. *Drug Development Research*, **1999**, 46, 57-66	5.1
10	British neurology: a national focus. *Journal of Neurology, Neurosurgery and Psychiatry*, **1994**, 57, 1136	5.5
9	How does lignocaine prevent ventricular fibrillation?. *Lancet, The*, **1981**, 2, 1167-8	40
8	The use of toxins to elucidate neural function and disease. *Current Opinion in Neurology and Neurosurgery*, **1993**, 6, 448-51	
7	Neuroprotection in Parkinson Disease. *Advances in Behavioral Biology*, **2002**, 373-378	
6	Colloidal gold staining and immunodetection in 2D protein mapping. *Methods in Molecular Biology*, **1998**, 80, 237-41	1.4
5	L444P Gba1 mutation increases formation and spread of synuclein deposits in mice injected with mouse synuclein pre-formed fibrils **2020**, 15, e0238075	
4	L444P Gba1 mutation increases formation and spread of synuclein deposits in mice injected with mouse synuclein pre-formed fibrils **2020**, 15, e0238075	
3	L444P Gba1 mutation increases formation and spread of synuclein deposits in mice injected with mouse synuclein pre-formed fibrils **2020**, 15, e0238075	
2	L444P Gba1 mutation increases formation and spread of synuclein deposits in mice injected with mouse synuclein pre-formed fibrils **2020**, 15, e0238075	
1	Somatic copy number variant mutations in alpha-synuclein and genome-wide in brains of synucleinopathy cases. *Journal of Neurology, Neurosurgery and Psychiatry*, **2022**, 93, A4.2-A4	5.5